Octagon Capital Advisors LP 13D and 13G filings for Xilio Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-06 4:04 pm Sale |
2024-01-02 | 13G | Xilio Therapeutics, Inc. XLO |
Octagon Capital Advisors LP | 0 0.000% |
-1,785,000 (Position Closed) |
Filing |
| 2024-02-05 4:01 pm Sale |
2023-12-31 | 13G | Xilio Therapeutics, Inc. XLO |
Octagon Capital Advisors LP | 1,785,000 6.480% |
-640,000 (-26.39%) |
Filing |
| 2023-01-25 4:01 pm Purchase |
2022-12-31 | 13G | Xilio Therapeutics, Inc. XLO |
Octagon Capital Advisors LP | 2,425,000 8.830% |
2,425,000 (New Position) |
Filing |